A randomized, double blind trial of LdT (telbivudine) versus lamivudine in adults with compensated chronic hepatitis B

Trial Profile

A randomized, double blind trial of LdT (telbivudine) versus lamivudine in adults with compensated chronic hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2015

At a glance

  • Drugs Telbivudine (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOBE
  • Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 01 Feb 2009 2-year results published in Gastroenterology.
    • 20 Dec 2007 Week 52 results published in full in New England Journal of Medicine (NEJM) 357: 2576-2588, No. 25, 20 Dec 2007.
    • 27 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top